Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Two Doses of Orbactiv in ABSSSI
NCT02925416Phase 4Completed
- Sponsor
- The Medicines Company
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute bacterial skin and skin structure infection (ABSSSI) comparing Oritavancin/Oritavancin with Oritavancin/Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 21. Started Jan 2017; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02925416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925416.